πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to SELLAS Life Sciences Group, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

EVOMELA

CASI Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes therapeutics and pharmaceutical products focusing on markets in China, the United States, and internationally. Major products include EVOMELA and a pipeline with several investigational products targeting various cancers.

Tags: CAR-T, biopharmaceutical, cancer treatment, clinical trials, multiple myeloma, pharmaceutical, therapeutics

Symbol: CASI

Recent Price: $2.93

Industry: Biotechnology

CEO: Dr. Wei-Wu He Ph.D.

Sector: Healthcare

Employees: 176

Address: 9620 Medical Center Drive, Rockville, MD 20850

Phone: 240 864 2600

Last updated: 2024-12-31

Galera Therapeutics, Inc.

Galera Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

avasopasem manganese (GC4419)

Galera Therapeutics, Inc. is a clinical stage biopharmaceutical company focusing on developing and commercializing therapeutics aimed at transforming radiotherapy in cancer. Their lead product candidate, avasopasem manganese, has completed a Phase III clinical trial targeting oral mucositis in head and neck cancer patients.

Tags: biopharmaceutical, cancer treatment, clinical trials, radiotherapy, superoxide dismutase mimetic

Symbol: GRTX

Recent Price: $0.03

Industry: Biotechnology

CEO: Dr. J. Mel Sorensen M.D.

Sector: Healthcare

Employees: 7

Address: 2 West Liberty Boulevard, Malvern, PA 19355

Phone: 610 725 1500

Leadership

  • J. Mel Sorensen, MD, President and Chief Executive Officer
  • Lawrence Alleva, Chair of the Board of Directors
  • Emmett Cunningham, MD, PhD, Board Member
  • Kevin Lokay, MS, Board Member
  • Michael Powell, PhD, Chair of the Nominating and Corporate Governance Committee
  • Linda West, Chair of the Compensation Committee

Last updated: 2024-12-31

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. logo
Market Cap: Low
Employees: Low

LYL797, LYL845, NY-ESO-1

Lyell Immunopharma, Inc. is a biopharmaceutical company developing T cell therapies focused on treating patients with solid tumors using advanced genetic and epigenetic reprogramming technologies.

Tags: T cell therapy, biotechnology, cancer treatment, epigenetic reprogramming, genetic reprogramming, solid tumors

Symbol: LYEL

Recent Price: $0.62

Industry: Biotechnology

CEO: Dr. Lynn Seely M.D., Ph.D.

Sector: Healthcare

Employees: 224

Address: 201 Haskins Way, South San Francisco, CA 94080

Phone: 650 695 0677

Leadership

  • Lynn Seely, M.D., President & Chief Executive Officer
  • Stephen Hill, Chief Operating Officer
  • Matthew Lang, J.D., Chief Business Officer
  • Gary Lee, Ph.D., Chief Scientific Officer
  • Charles Newton, Chief Financial Officer
  • Ellen Rose, Senior Vice President, Investor Relations and Communications
  • Bryan Selby, Senior Vice President, Clinical Development Operations
  • Ann Tomlin, Senior Vice President, Human Resources
  • Rick Klausner, M.D., Founder & Board Chair
  • Crystal Mackall, M.D., Founder
  • Stan Riddell, M.D., Founder
  • Hans Bishop, Director
  • Otis Brawley, M.D., Director
  • Catherine Friedman, Director
  • Elizabeth Nabel, M.D., Director
  • Robert Nelsen, Director
  • William Rieflin, Director

Last updated: 2024-12-31

Apollomics, Inc.

Apollomics, Inc. logo
Market Cap: Lowest
Employees: Lowest

APL-101 (Vebreltinib), APL-102, APL-122

Apollomics, Inc. is a biotechnology company that discovers and develops oncology therapies to address unmet medical needs, focusing on treatments for non-small cell lung cancer, liver cancer, breast cancer, esophageal cancer, and brain tumors.

Tags: biotechnology, brain tumors, c-Met inhibitor, cancer therapy, non-small cell lung cancer, oncology, tyrosine kinase inhibitor

Symbol: APLM

Recent Price: $10.13

Industry: Biotechnology

CEO: Dr. Guo-Liang Yu Ph.D.

Sector: Healthcare

Employees: 45

Address: 989 East Hillsdale Blvd, Foster City, CA 94404

Phone: 650 209 4055

Last updated: 2024-12-31

Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Medium

pegcetacoplan

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds targeting the complement system for autoimmune and inflammatory diseases.

Tags: autoimmune diseases, biopharmaceutical, complement system, inflammatory diseases, pegcetacoplan, therapeutics

Symbol: APLS

Recent Price: $31.90

Industry: Biotechnology

CEO: Dr. Cedric Francois M.D., Ph.D.

Sector: Healthcare

Employees: 702

Address: 100 Fifth Avenue, Waltham, MA 02451

Phone: 617 977 5700

Leadership

  • Cedric Francois, MD, PhD, Co-Founder & Chief Executive Officer/President
  • Caroline Baumal, MD, Chief Medical Officer
  • Mark DeLong, Chief Business & Strategy Officer
  • Pascal Deschatelets, PhD, Co-Founder & Chief Scientific Officer
  • Jeffrey Eisele, PhD, Chief Development Officer
  • Karen Lewis, Chief People Officer
  • Nur Nicholson, Chief Technical Operations Officer
  • Timothy Sullivan, Chief Financial Officer
  • Adam Townsend, Chief Operating Officer
  • David Watson, JD, General Counsel
  • Apellis Pharmaceuticals,
  • Gerald Chan, Chairman
  • Sinclair Dunlop, Director
  • Stephanie Monaghan O’Brien, Director
  • Paul Fonteyne, Director
  • Cedric Francois, Co-Founder & Chief Executive Officer/President
  • Alec Machiels, Co-Founder

Last updated: 2024-12-31

89bio, Inc.

89bio, Inc. logo
Market Cap: Medium
Employees: Low

pegozafermin

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardio-metabolic diseases, primarily through its lead product candidate, pegozafermin, designed to treat nonalcoholic steatohepatitis and severe hypertriglyceridemia.

Tags: biopharmaceutical, cardio-metabolic, clinical-stage, hypertriglyceridemia, liver diseases, nonalcoholic steatohepatitis, pegozafermin

Symbol: ETNB

Recent Price: $7.87

Industry: Biotechnology

CEO: Mr. Rohan Palekar

Sector: Healthcare

Employees: 70

Address: 142 Sansome Street, San Francisco, CA 94104

Phone: 415 432 9270

Last updated: 2024-12-31

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

IGALMI

Bio Xcel Therapeutics, Inc. is a biopharmaceutical company leveraging artificial intelligence for developing transformative medicines in neuroscience and immuno-oncology. It focuses on re-innovating existing drugs with machine learning to identify new therapeutic uses.

Tags: agitation treatment, artificial intelligence, biopharmaceutical, clinical trials, immuno-oncology, neuroscience

Symbol: BTAI

Recent Price: $0.37

Industry: Biotechnology

CEO: Dr. Vimal D. Mehta Ph.D.

Sector: Healthcare

Employees: 74

Address: 555 Long Wharf Drive, New Haven, CT 06511

Phone: 475 238 6837

Last updated: 2024-12-31

Celularity Inc.

Celularity Inc. logo
Market Cap: Lowest
Employees: Low

CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.

Tags: biotechnology, cancer, cell therapies, immune diseases, infectious diseases, placental-derived

Symbol: CELU

Recent Price: $2.05

Industry: Biotechnology

CEO: Dr. Robert Joseph Hariri M.D., Ph.D.

Sector: Healthcare

Employees: 120

Address: 170 Park Avenue, Florham Park, NJ 07932

Phone: 908 768 2170

Leadership

  • Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
  • David Beers, CFA, Chief Financial Officer
  • Stephen Brigido, DPM, President, Degenerative Diseases
  • John Haines, Global Manager and Chief Administrative Officer
  • K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
  • John Colerangle, DVM, Ph.D., Regulatory Affairs
  • Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
  • Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
  • Carmine Palummo, Corporate Operations
  • Tim Wilk, Technical Operations
  • Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
  • Peter Diamandis, M.D., Director
  • Dean Kehler, Director
  • Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
  • Diane Parks, Director

Last updated: 2024-12-31

Galectin Therapeutics Inc.

Galectin Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

belapectin (GR-MD-02)

Galectin Therapeutics Inc. engages in research and development of therapies for fibrotic, cancer, and other diseases, with a focus on developing galectin-3 inhibitors like belapectin.

Tags: biopharmaceutical, cancer therapy, clinical stage, fibrosis, galectin-3 inhibitor

Symbol: GALT

Recent Price: $1.10

Industry: Biotechnology

CEO: Mr. Joel Lewis

Sector: Healthcare

Employees: 14

Address: 4960 Peachtree Industrial Boulevard, Norcross, GA 30071

Phone: 678 620 3186

Last updated: 2024-12-31

Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. logo
Market Cap: Low
Employees: Lowest

GP2

Greenwich Life Sciences, Inc. is a clinical stage biopharmaceutical company focusing on developing novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers, with a lead product candidate GP2, which aims to prevent breast cancer recurrences.

Tags: GP2, HER2/neu, biopharmaceutical, breast cancer, cancer immunotherapy, clinical trial

Symbol: GLSI

Recent Price: $10.91

Industry: Biotechnology

CEO: Mr. Snehal S. Patel

Sector: Healthcare

Employees: 3

Address: Building 14, Stafford, TX 77477

Phone: 832 819 3232

Last updated: 2024-12-31

Gossamer Bio, Inc.

Gossamer Bio, Inc. logo
Market Cap: Low
Employees: Low

GB002, GB004, GB5121, GB7208

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics in immunology, inflammation, and oncology. Key products in development include GB002 for pulmonary arterial hypertension, GB004 for inflammatory bowel disease, GB5121 for primary central nervous system lymphoma, and GB7208 for multiple sclerosis.

Tags: biopharmaceutical, central nervous system lymphoma, immunology, inflammation, inflammatory bowel disease, multiple sclerosis, oncology, pulmonary arterial hypertension, therapeutics

Symbol: GOSS

Recent Price: $0.88

Industry: Biotechnology

CEO: Mr. Faheem Hasnain

Sector: Healthcare

Employees: 135

Address: 3013 Science Park Road, San Diego, CA 92121

Phone: 858 684 1300

Leadership

  • Faheem Hasnain, Chairman
  • Richard Aranda, M.D., Chief Medical Officer
  • Jeff Boerneke, General Counsel and Secretary
  • Matt Cravets, Senior Vice President, Biometrics
  • Bryan Giraudo, Chief Operating Officer & Chief Financial Officer
  • Lisa Nolan, Ph.D., Managing Director and President, Gossamer Bio Ireland
  • Caryn Peterson, Executive Vice President, Regulatory Affairs
  • Bob Smith, Chief Commercial Officer
  • Christian Waage, Executive Vice President, Technical Operations & Administration
  • Deanna Weber, Senior Vice President, Human Resources
  • Russell J. Cox, Director
  • Thomas Daniel, Director
  • Skye Drynan, Director
  • Sandra Milligan, Director
  • Steven D. Nathan, Director
  • John Quisel, Director

Last updated: 2024-12-31

GeoVax Labs, Inc.

GeoVax Labs, Inc. logo
Market Cap: Lowest
Employees: Lowest

Modified Vaccinia Ankara Virus-Like Particle Vaccine Platform

Geo Vax Labs, Inc. develops human vaccines and immunotherapies against infectious diseases and cancers using its proprietary modified vaccinia ankara virus-like particle vaccine platform. The company focuses on preventive vaccines for diseases like COVID-19, HIV, Zika, malaria, and hemorrhagic fever viruses, as well as therapeutic vaccines for HIV and chronic Hepatitis B.

Tags: biotechnology, cancer, immunotherapy, infectious diseases, vaccines

Symbol: GOVX

Recent Price: $2.44

Industry: Biotechnology

CEO: Mr. David Alan Dodd

Sector: Healthcare

Employees: 17

Address: 1900 Lake Park Drive, Smyrna, GA 30080

Phone: 678 384 7220

Last updated: 2024-12-31

PDS Biotechnology Corporation

PDS Biotechnology Corporation logo
Market Cap: Low
Employees: Lowest

PDS0101

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing multifunctional cancer immunotherapies. Its lead product candidate, PDS0101, is in Phase II clinical trial for treating various human papillomavirus-associated malignancies.

Tags: biopharmaceutical, cancer immunotherapies, clinical trials, clinical-stage, oncology, vaccines

Symbol: PDSB

Recent Price: $1.69

Industry: Biotechnology

CEO: Dr. Frank K. Bedu-Addo Ph.D.

Sector: Healthcare

Employees: 25

Address: 25B Vreeland Road, Florham Park, NJ 07932

Phone: 800 208 3343

Leadership

  • Frank Bedu-Addo, Ph.D., Chief Executive Officer, Director
  • Stephan Toutain, Chief Operating Officer
  • Lars Boesgaard, Chief Financial Officer
  • Gregory Conn, Ph.D., Chief Scientific Officer
  • Kirk Shepard, M.D., Chief Medical Officer
  • Spencer Brown, Senior Vice-President, General Counsel, Corporate Secretary and Compliance Officer
  • Rory Cullinane, Vice President of Quality
  • Joe Dervan, Ph.D., Vice President of Research and Development
  • David Schaaf, M.D., Vice President of Medical Affairs
  • Sir Richard Sykes, Director
  • Ilian Iliev, Ph.D., Director
  • Gregory Freitag, J.D., CPA, Director
  • Otis W. Brawley, M.D., Director
  • Kamil Ali-Jackson, J.D., Director
  • Stephen Glover, Chairman

Last updated: 2024-12-31

Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

SEL-302, SEL-212

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for treating and preventing human diseases. The company has various programs including gene therapies and biologic therapies for conditions like methylmalonic acidemia and chronic refractory gout.

Tags: autoimmune diseases, biologic therapies, biopharmaceutical, gene therapy, nanoparticle drugs

Symbol: RNAC

Recent Price: $18.76

Industry: Biotechnology

CEO: Dr. Carsten Brunn Ph.D.

Sector: Healthcare

Employees: 37

Address: 65 Grove Street, Watertown, MA 02472

Phone: 617 923 1400

Last updated: 2024-12-31

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. logo
Market Cap: Low
Employees: Lowest

galinpepimut-S (GPS)

SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focusing on the development of novel cancer immunotherapies in the United States. Their lead product candidate, galinpepimut-S (GPS), is in Phase III clinical trials for acute myeloid leukemia and Phase 1/2 for ovarian cancer.

Tags: acute myeloid leukemia, biopharmaceutical, breast cancer, cancer immunotherapies, clinical trials, ovarian cancer

Symbol: SLS

Recent Price: $0.99

Industry: Biotechnology

CEO: Dr. Angelos M. Stergiou M.D., ScD h.c.

Sector: Healthcare

Employees: 16

Address: Times Square Tower, New York, NY 10036

Phone: 646 200 5278

Last updated: 2024-12-31

Globus Medical, Inc.

Globus Medical, Inc. logo
Market Cap: Highest
Employees: High

Healthcare Solutions

Globus Medical, Inc. develops and commercializes healthcare solutions for musculoskeletal disorders, offering spine products, motion preservation technologies, and treatment for orthopedic trauma among others.

Tags: healthcare, medical devices, orthopedic trauma, regenerative biologics, spine products

Symbol: GMED

Recent Price: $82.67

Industry: Medical - Devices

CEO: Mr. Daniel T. Scavilla

Sector: Healthcare

Employees: 5000

Address: 2560 General Armistead Avenue, Audubon, PA 19403

Phone: 610 930 1800

Last updated: 2024-12-31

Galecto, Inc.

Galecto, Inc. logo
Market Cap: Lowest
Employees: Lowest

GB2064

Galecto, Inc. is a clinical-stage biotechnology company focused on developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Their lead product candidate, GB2064, is in Phase IIa for myelofibrosis. The company also advances other candidates targeting severe fibrotic lung diseases and cancer.

Tags: biotechnology, cancer, clinical trials, fibrosis, inflammation, pharmaceutical

Symbol: GLTO

Recent Price: $4.60

Industry: Biotechnology

CEO: Dr. Hans T. Schambye M.D., Ph.D.

Sector: Healthcare

Employees: 13

Address: 75 State Street, Boston, MA 02109

Phone: 457 070 5210

Last updated: 2024-12-31

Panbela Therapeutics, Inc.

Panbela Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SBP-101

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for treating various cancers, including pancreatic and ovarian cancers. Its lead product, SBP-101, is undergoing clinical trials for pancreatic cancer treatment.

Tags: biopharmaceutical, cancer treatment, clinical trials, pancreatic cancer, therapeutics

Symbol: PBLA

Recent Price: $0.32

Industry: Biotechnology

CEO: Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.

Sector: Healthcare

Employees: 7

Address: 712 Vista Boulevard, Waconia, MN 55387

Phone: 952 479 1196

Leadership

  • Michael T. Cullen, MD, MBA, Chairman, President and Chief Executive Officer
  • Jennifer K Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer
  • Art Fratamico, MBA, Chief Business Officer
  • Dan Donovan, CEO of rareLife Solutions, Inc.
  • Jeff Mathiesen, Director and Audit Committee Chair
  • Jeffrey Jacob, CEO at Cancer Prevention Pharmaceuticals, Inc.
  • Robert Schemel, Director
  • David Harle, Ph.D., Executive with over 25 years of pharmaceutical experience
  • Mr. Donovan, CEO of rareLife Solutions, Inc.

Last updated: 2024-12-31

Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SLS-002, SLS-005, SLS-006, SLS-007, SLS-008, SLS-004, SLS-010

Seelos Therapeutics, Inc. is focused on developing and commercializing therapeutics for central nervous system, respiratory, and other disorders, with lead programs targeting major depressive disorders, amyotrophic lateral sclerosis, Sanfilippo syndrome, and Parkinson's disease.

Tags: ALS, Parkinson's disease, Sanfilippo syndrome, biopharmaceutical, central nervous system, major depressive disorder, respiratory disorders, therapeutics

Symbol: SEEL

Recent Price: $0.37

Industry: Biotechnology

CEO: Dr. Raj Mehra J.D., Ph.D.

Sector: Healthcare

Employees: 8

Address: 300 Park Avenue, New York, NY 10022

Phone: 646 293 2100

Last updated: 2024-12-31

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31